TrialCalcified tissue international2013

Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.

Toshitaka Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.